About Beam Therapeutics
Beam Therapeutics is a company based in Cambridge (United States) founded in 2017 by Keith Joung and David Liu. Beam Therapeutics has raised $222 million across 4 funding rounds from investors including Sana Biotechnology, Arch Venture Partners and Eight Roads Ventures. The company has 483 employees as of December 31, 2024. Beam Therapeutics has completed 1 acquisition, including GuideTX. Beam Therapeutics offers products and services including Base Editing Technology. Beam Therapeutics operates in a competitive market with competitors including eGenesis, Korro Bio, Editas Medicine, Intellia Therapeutics and Metagenomi, among others.
- Headquarter Cambridge, United States
- Employees 483 as on 31 Dec, 2024
- Founders Keith Joung, David Liu
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Beam Therapeutics Inc.
-
Annual Revenue
$63.52 M (USD)-83.18as on Dec 31, 2024
-
Net Profit
-$376.74 M (USD)-184.28as on Dec 31, 2024
-
EBITDA
-$393.64 M (USD)-151.57as on Dec 31, 2024
-
Total Equity Funding
$222 M (USD)
in 4 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Oct 19, 2021
-
Investors
Sana Biotechnology
& 8 more
-
Employee Count
483
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Beam Therapeutics
Beam Therapeutics is a publicly listed company on the NASDAQ with ticker symbol BEAM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Beam Therapeutics
Beam Therapeutics offers a comprehensive portfolio of products and services, including Base Editing Technology.
Precision tool for modifying DNA bases in genetic therapies
People of Beam Therapeutics
Unlock access to complete
Unlock access to complete
Leadership Team
48 people
Software Development Team
36 people
Senior Team
27 people
Product Management Team
18 people
Operations Team
11 people
Finance and Accounting
9 people
Legal and Compliance
8 people
Principal Team
7 people
Unlock access to complete
Funding Insights of Beam Therapeutics
Beam Therapeutics has successfully raised a total of $222M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Beam Therapeutics
Beam Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Sana Biotechnology, Arch Venture Partners and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage life sciences sectors focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Beam Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Beam Therapeutics
Beam Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GuideTX.
Investment portfolio details for Beam Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Technology for DNA and RNA delivery to targets is provided.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Beam Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Beam Therapeutics
Detailed financials for Beam Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Beam Therapeutics Comparisons
Peer comparison for Beam Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Beam Therapeutics
Beam Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as eGenesis, Korro Bio, Editas Medicine, Intellia Therapeutics and Metagenomi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Therapeutics using CRISPR/Cas9 are developed for various diseases.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
Detailed competitors of Beam Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Beam Therapeutics
Complete news archive for Beam Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Beam Therapeutics
Beam Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Beam Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John Evans is the current CEO of Beam Therapeutics.
Beam Therapeutics is a funded company, having raised a total of $222M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Beam Therapeutics is 483.
Annual revenue of Beam Therapeutics is $63.52M as on Dec 31, 2024.
Beam Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed using CRISPR base editing technology to address conditions including sickle cell disease, thalassemia, leukemia, liver disorders, and ocular diseases. Specific base pairs in DNA or RNA are targeted and edited to correct point mutations, with operations focused on advancing these treatments through research and development.
Beam Therapeutics's top competitors include eGenesis, Tessera Therapeutics and Korro Bio.
Beam Therapeutics offers Base Editing Technology.
Yes, Beam Therapeutics is publicly traded on NASDAQ under the ticker symbol BEAM.
Beam Therapeutics has made 1 acquisition, including GuideTX.
Beam Therapeutics has 9 investors. Key investors include Sana Biotechnology, Arch Venture Partners, Eight Roads Ventures, Altitude Life Science Ventures, and Google Ventures.
The ticker symbol of Beam Therapeutics is BEAM on NASDAQ.